Global Active Pharmaceutical Ingredients research

Active Pharmaceutical Ingredients Comprehensive Study by Type (Innovative Active Pharmaceutical Ingredients, Generic Active Pharmaceutical Ingredients), Synthesis (Biotech, Synthetic), Manufacturer (Captive API Manufacturers, Merchant API Manufacturers), Therapy Area (Oncology, Non-Steroidal Anti-Inflammatory, Cardiovascular, Anti-Diabetic, Neurology (Biperiden HCL, Other Neurology API), Musculoskeletal, Others) Players and Region - Global Market Outlook to 2030

Active Pharmaceutical Ingredients Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Active Pharmaceutical Ingredients
Active pharmaceutical ingredient (API) refers to drug with wide ranges of biologically active substances such as synthetic, biotechnological and natural products that are used to manufacture pharmaceutical drugs. These drugs are intended to provide direct effect in the diagnosis process. Active pharmaceutical ingredient market has high growth prospects owing to increasing number of chronic diseases. For instance, according to World Health Organization (WHO) in 2018, cancer led to 9.6 million deaths globally, and cardiovascular disease accounted for nearly 836,546 deaths in the United States and 3.9 million deaths in Europe which are driving the need to develop novel drugs. Further, increasing demand from emerging economies and technological advancement in the API industry expected to drive the demand for API over the forecasted period.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The competitive landscape of active pharmaceutical ingredients (APIs) is highly dynamic and competitive due to the growing demand for pharmaceutical products worldwide. Major global players like Pfizer, Novartis, Teva Pharmaceutical Industries, Sanofi, and Merck & Co. dominate the API market. It's important to note that the competitive landscape can vary depending on the specific therapeutic area, geographical region, and the type of API involved. Market dynamics, mergers and acquisitions, and regulatory changes can also influence the competitive landscape over time. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Active Pharmaceutical Ingredients market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Pfizer, Inc. (United States), Novartis AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (United States), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company (United States), GlaxoSmithKline plc (United Kingdom), Merck & Co., Inc. (United States), Sun Pharmaceutical Industries Ltd. (India), F. Hoffmann-La Roche Ltd. (Switzerland) and AstraZeneca plc (United Kingdom) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Olon S.p.A. (Italy), ZETA (Austria), AbbVie Inc. (United States), Corden Pharma (Germany) and Inalco Pharma (United States).

Segmentation Overview
AMA Research has segmented the market of Global Active Pharmaceutical Ingredients market by Type (Innovative Active Pharmaceutical Ingredients and Generic Active Pharmaceutical Ingredients) and Region.



On the basis of geography, the market of Active Pharmaceutical Ingredients has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Synthesis, the sub-segment i.e. Biotech will boost the Active Pharmaceutical Ingredients market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Manufacturer, the sub-segment i.e. Captive API Manufacturers will boost the Active Pharmaceutical Ingredients market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Therapy Area, the sub-segment i.e. Oncology will boost the Active Pharmaceutical Ingredients market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Growing Focus of Biopharmaceutical Industry on Gene Editing Technology and Emphasizing On Polymorphism of Active Pharmaceutical Ingredients

Market Growth Drivers:
Increasing Number of Patients with Chronic Diseases and Emergence of Artificial Intelligence-Based Tools for Drug Discovery

Challenges:
Lack of Advance Healthcare Infrastructure in Emerging Countries

Restraints:
High Manufacturing Cost of Active Pharmaceutical Ingredient and Stringent Regulatory Framework Regarding Drugs Approval

Opportunities:
Increasing Demand from Developing Countries Owing to Growing Healthcare Infrastructure and Rise in Demand of Precision and Generic Medicines

Market Leaders and their expansionary development strategies
21st march 2019, Pfizer a research-based biopharmaceutical company collaborated with Vivet Therapeutics. As Pfizer announced, it has acquired 15% of equity interest in Vivet Therapeutics with the option to acquire all outstanding shares in near future. and 2nd April 2019, Novartis acquired IFM Tre a biopharmaceutical company. This acquisition will help Novartis to expand its portfolio in immunomodulatory medicines.
1st April 2019, Olon S.p.A., engaged in development and production of APIs, generic drug and contract development and manufacturing (CDMO) services announced acquisition of the manufacturing facility in Mahad, India. This will help company to expand their footprints in the Indian market.
“According to Food and Drug Administration (FDA) the ICH guidance Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients is intended to provide guidance regarding good manufacturing practice (GMP) for the manufacturing of active pharmaceutical ingredients (APIs) under an appropriate system for managing quality. It is also intended to help ensure that APIs meet the quality and purity characteristics that they purport, or are represented, to possess.”

Key Target Audience
API Manufacturer, Healthcare Institutions (Hospitals, Medical Schools, and Outpatient Clinics), Biopharmaceutical Companies, Potential Investors, Contract Development and Manufacturing Organization (CDMO), Clinical Research Organizations/ Contract Research Organizations, Market Research and Consulting Firms and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Innovative Active Pharmaceutical Ingredients
  • Generic Active Pharmaceutical Ingredients
By Synthesis
  • Biotech
  • Synthetic

By Manufacturer
  • Captive API Manufacturers
  • Merchant API Manufacturers

By Therapy Area
  • Oncology
  • Non-Steroidal Anti-Inflammatory
  • Cardiovascular
  • Anti-Diabetic
  • Neurology [Biperiden HCL, Other Neurology API]
  • Musculoskeletal
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Number of Patients with Chronic Diseases
      • 3.2.2. Emergence of Artificial Intelligence-Based Tools for Drug Discovery
    • 3.3. Market Challenges
      • 3.3.1. Lack of Advance Healthcare Infrastructure in Emerging Countries
    • 3.4. Market Trends
      • 3.4.1. Growing Focus of Biopharmaceutical Industry on Gene Editing Technology
      • 3.4.2. Emphasizing On Polymorphism of Active Pharmaceutical Ingredients
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Active Pharmaceutical Ingredients, by Type, Synthesis, Manufacturer, Therapy Area and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Active Pharmaceutical Ingredients (Value)
      • 5.2.1. Global Active Pharmaceutical Ingredients by: Type (Value)
        • 5.2.1.1. Innovative Active Pharmaceutical Ingredients
        • 5.2.1.2. Generic Active Pharmaceutical Ingredients
      • 5.2.2. Global Active Pharmaceutical Ingredients by: Synthesis (Value)
        • 5.2.2.1. Biotech
        • 5.2.2.2. Synthetic
      • 5.2.3. Global Active Pharmaceutical Ingredients by: Manufacturer (Value)
        • 5.2.3.1. Captive API Manufacturers
        • 5.2.3.2. Merchant API Manufacturers
      • 5.2.4. Global Active Pharmaceutical Ingredients by: Therapy Area (Value)
        • 5.2.4.1. Oncology
        • 5.2.4.2. Non-Steroidal Anti-Inflammatory
        • 5.2.4.3. Cardiovascular
        • 5.2.4.4. Anti-Diabetic
        • 5.2.4.5. Neurology [Biperiden HCL, Other Neurology API]
        • 5.2.4.6. Musculoskeletal
        • 5.2.4.7. Others
      • 5.2.5. Global Active Pharmaceutical Ingredients Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. Australia
          • 5.2.5.2.5. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Active Pharmaceutical Ingredients (Price)
      • 5.3.1. Global Active Pharmaceutical Ingredients by: Type (Price)
  • 6. Active Pharmaceutical Ingredients: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sanofi (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Boehringer Ingelheim (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bristol-Myers Squibb (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Eli Lilly and Company (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GlaxoSmithKline plc (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Merck & Co., Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sun Pharmaceutical Industries Ltd. (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. AstraZeneca plc (United Kingdom)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Active Pharmaceutical Ingredients Sale, by Type, Synthesis, Manufacturer, Therapy Area and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Active Pharmaceutical Ingredients (Value)
      • 7.2.1. Global Active Pharmaceutical Ingredients by: Type (Value)
        • 7.2.1.1. Innovative Active Pharmaceutical Ingredients
        • 7.2.1.2. Generic Active Pharmaceutical Ingredients
      • 7.2.2. Global Active Pharmaceutical Ingredients by: Synthesis (Value)
        • 7.2.2.1. Biotech
        • 7.2.2.2. Synthetic
      • 7.2.3. Global Active Pharmaceutical Ingredients by: Manufacturer (Value)
        • 7.2.3.1. Captive API Manufacturers
        • 7.2.3.2. Merchant API Manufacturers
      • 7.2.4. Global Active Pharmaceutical Ingredients by: Therapy Area (Value)
        • 7.2.4.1. Oncology
        • 7.2.4.2. Non-Steroidal Anti-Inflammatory
        • 7.2.4.3. Cardiovascular
        • 7.2.4.4. Anti-Diabetic
        • 7.2.4.5. Neurology [Biperiden HCL, Other Neurology API]
        • 7.2.4.6. Musculoskeletal
        • 7.2.4.7. Others
      • 7.2.5. Global Active Pharmaceutical Ingredients Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. Australia
          • 7.2.5.2.5. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Active Pharmaceutical Ingredients (Price)
      • 7.3.1. Global Active Pharmaceutical Ingredients by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Active Pharmaceutical Ingredients: by Type(USD Million)
  • Table 2. Active Pharmaceutical Ingredients Innovative Active Pharmaceutical Ingredients , by Region USD Million (2018-2023)
  • Table 3. Active Pharmaceutical Ingredients Generic Active Pharmaceutical Ingredients , by Region USD Million (2018-2023)
  • Table 4. Active Pharmaceutical Ingredients: by Synthesis(USD Million)
  • Table 5. Active Pharmaceutical Ingredients Biotech , by Region USD Million (2018-2023)
  • Table 6. Active Pharmaceutical Ingredients Synthetic , by Region USD Million (2018-2023)
  • Table 7. Active Pharmaceutical Ingredients: by Manufacturer(USD Million)
  • Table 8. Active Pharmaceutical Ingredients Captive API Manufacturers , by Region USD Million (2018-2023)
  • Table 9. Active Pharmaceutical Ingredients Merchant API Manufacturers , by Region USD Million (2018-2023)
  • Table 10. Active Pharmaceutical Ingredients: by Therapy Area(USD Million)
  • Table 11. Active Pharmaceutical Ingredients Oncology , by Region USD Million (2018-2023)
  • Table 12. Active Pharmaceutical Ingredients Non-Steroidal Anti-Inflammatory , by Region USD Million (2018-2023)
  • Table 13. Active Pharmaceutical Ingredients Cardiovascular , by Region USD Million (2018-2023)
  • Table 14. Active Pharmaceutical Ingredients Anti-Diabetic , by Region USD Million (2018-2023)
  • Table 15. Active Pharmaceutical Ingredients Neurology [Biperiden HCL, Other Neurology API] , by Region USD Million (2018-2023)
  • Table 16. Active Pharmaceutical Ingredients Musculoskeletal , by Region USD Million (2018-2023)
  • Table 17. Active Pharmaceutical Ingredients Others , by Region USD Million (2018-2023)
  • Table 18. South America Active Pharmaceutical Ingredients, by Country USD Million (2018-2023)
  • Table 19. South America Active Pharmaceutical Ingredients, by Type USD Million (2018-2023)
  • Table 20. South America Active Pharmaceutical Ingredients, by Synthesis USD Million (2018-2023)
  • Table 21. South America Active Pharmaceutical Ingredients, by Manufacturer USD Million (2018-2023)
  • Table 22. South America Active Pharmaceutical Ingredients, by Therapy Area USD Million (2018-2023)
  • Table 23. Brazil Active Pharmaceutical Ingredients, by Type USD Million (2018-2023)
  • Table 24. Brazil Active Pharmaceutical Ingredients, by Synthesis USD Million (2018-2023)
  • Table 25. Brazil Active Pharmaceutical Ingredients, by Manufacturer USD Million (2018-2023)
  • Table 26. Brazil Active Pharmaceutical Ingredients, by Therapy Area USD Million (2018-2023)
  • Table 27. Argentina Active Pharmaceutical Ingredients, by Type USD Million (2018-2023)
  • Table 28. Argentina Active Pharmaceutical Ingredients, by Synthesis USD Million (2018-2023)
  • Table 29. Argentina Active Pharmaceutical Ingredients, by Manufacturer USD Million (2018-2023)
  • Table 30. Argentina Active Pharmaceutical Ingredients, by Therapy Area USD Million (2018-2023)
  • Table 31. Rest of South America Active Pharmaceutical Ingredients, by Type USD Million (2018-2023)
  • Table 32. Rest of South America Active Pharmaceutical Ingredients, by Synthesis USD Million (2018-2023)
  • Table 33. Rest of South America Active Pharmaceutical Ingredients, by Manufacturer USD Million (2018-2023)
  • Table 34. Rest of South America Active Pharmaceutical Ingredients, by Therapy Area USD Million (2018-2023)
  • Table 35. Asia Pacific Active Pharmaceutical Ingredients, by Country USD Million (2018-2023)
  • Table 36. Asia Pacific Active Pharmaceutical Ingredients, by Type USD Million (2018-2023)
  • Table 37. Asia Pacific Active Pharmaceutical Ingredients, by Synthesis USD Million (2018-2023)
  • Table 38. Asia Pacific Active Pharmaceutical Ingredients, by Manufacturer USD Million (2018-2023)
  • Table 39. Asia Pacific Active Pharmaceutical Ingredients, by Therapy Area USD Million (2018-2023)
  • Table 40. China Active Pharmaceutical Ingredients, by Type USD Million (2018-2023)
  • Table 41. China Active Pharmaceutical Ingredients, by Synthesis USD Million (2018-2023)
  • Table 42. China Active Pharmaceutical Ingredients, by Manufacturer USD Million (2018-2023)
  • Table 43. China Active Pharmaceutical Ingredients, by Therapy Area USD Million (2018-2023)
  • Table 44. Japan Active Pharmaceutical Ingredients, by Type USD Million (2018-2023)
  • Table 45. Japan Active Pharmaceutical Ingredients, by Synthesis USD Million (2018-2023)
  • Table 46. Japan Active Pharmaceutical Ingredients, by Manufacturer USD Million (2018-2023)
  • Table 47. Japan Active Pharmaceutical Ingredients, by Therapy Area USD Million (2018-2023)
  • Table 48. India Active Pharmaceutical Ingredients, by Type USD Million (2018-2023)
  • Table 49. India Active Pharmaceutical Ingredients, by Synthesis USD Million (2018-2023)
  • Table 50. India Active Pharmaceutical Ingredients, by Manufacturer USD Million (2018-2023)
  • Table 51. India Active Pharmaceutical Ingredients, by Therapy Area USD Million (2018-2023)
  • Table 52. Australia Active Pharmaceutical Ingredients, by Type USD Million (2018-2023)
  • Table 53. Australia Active Pharmaceutical Ingredients, by Synthesis USD Million (2018-2023)
  • Table 54. Australia Active Pharmaceutical Ingredients, by Manufacturer USD Million (2018-2023)
  • Table 55. Australia Active Pharmaceutical Ingredients, by Therapy Area USD Million (2018-2023)
  • Table 56. Rest of Asia-Pacific Active Pharmaceutical Ingredients, by Type USD Million (2018-2023)
  • Table 57. Rest of Asia-Pacific Active Pharmaceutical Ingredients, by Synthesis USD Million (2018-2023)
  • Table 58. Rest of Asia-Pacific Active Pharmaceutical Ingredients, by Manufacturer USD Million (2018-2023)
  • Table 59. Rest of Asia-Pacific Active Pharmaceutical Ingredients, by Therapy Area USD Million (2018-2023)
  • Table 60. Europe Active Pharmaceutical Ingredients, by Country USD Million (2018-2023)
  • Table 61. Europe Active Pharmaceutical Ingredients, by Type USD Million (2018-2023)
  • Table 62. Europe Active Pharmaceutical Ingredients, by Synthesis USD Million (2018-2023)
  • Table 63. Europe Active Pharmaceutical Ingredients, by Manufacturer USD Million (2018-2023)
  • Table 64. Europe Active Pharmaceutical Ingredients, by Therapy Area USD Million (2018-2023)
  • Table 65. Germany Active Pharmaceutical Ingredients, by Type USD Million (2018-2023)
  • Table 66. Germany Active Pharmaceutical Ingredients, by Synthesis USD Million (2018-2023)
  • Table 67. Germany Active Pharmaceutical Ingredients, by Manufacturer USD Million (2018-2023)
  • Table 68. Germany Active Pharmaceutical Ingredients, by Therapy Area USD Million (2018-2023)
  • Table 69. France Active Pharmaceutical Ingredients, by Type USD Million (2018-2023)
  • Table 70. France Active Pharmaceutical Ingredients, by Synthesis USD Million (2018-2023)
  • Table 71. France Active Pharmaceutical Ingredients, by Manufacturer USD Million (2018-2023)
  • Table 72. France Active Pharmaceutical Ingredients, by Therapy Area USD Million (2018-2023)
  • Table 73. Italy Active Pharmaceutical Ingredients, by Type USD Million (2018-2023)
  • Table 74. Italy Active Pharmaceutical Ingredients, by Synthesis USD Million (2018-2023)
  • Table 75. Italy Active Pharmaceutical Ingredients, by Manufacturer USD Million (2018-2023)
  • Table 76. Italy Active Pharmaceutical Ingredients, by Therapy Area USD Million (2018-2023)
  • Table 77. United Kingdom Active Pharmaceutical Ingredients, by Type USD Million (2018-2023)
  • Table 78. United Kingdom Active Pharmaceutical Ingredients, by Synthesis USD Million (2018-2023)
  • Table 79. United Kingdom Active Pharmaceutical Ingredients, by Manufacturer USD Million (2018-2023)
  • Table 80. United Kingdom Active Pharmaceutical Ingredients, by Therapy Area USD Million (2018-2023)
  • Table 81. Rest of Europe Active Pharmaceutical Ingredients, by Type USD Million (2018-2023)
  • Table 82. Rest of Europe Active Pharmaceutical Ingredients, by Synthesis USD Million (2018-2023)
  • Table 83. Rest of Europe Active Pharmaceutical Ingredients, by Manufacturer USD Million (2018-2023)
  • Table 84. Rest of Europe Active Pharmaceutical Ingredients, by Therapy Area USD Million (2018-2023)
  • Table 85. MEA Active Pharmaceutical Ingredients, by Country USD Million (2018-2023)
  • Table 86. MEA Active Pharmaceutical Ingredients, by Type USD Million (2018-2023)
  • Table 87. MEA Active Pharmaceutical Ingredients, by Synthesis USD Million (2018-2023)
  • Table 88. MEA Active Pharmaceutical Ingredients, by Manufacturer USD Million (2018-2023)
  • Table 89. MEA Active Pharmaceutical Ingredients, by Therapy Area USD Million (2018-2023)
  • Table 90. Middle East Active Pharmaceutical Ingredients, by Type USD Million (2018-2023)
  • Table 91. Middle East Active Pharmaceutical Ingredients, by Synthesis USD Million (2018-2023)
  • Table 92. Middle East Active Pharmaceutical Ingredients, by Manufacturer USD Million (2018-2023)
  • Table 93. Middle East Active Pharmaceutical Ingredients, by Therapy Area USD Million (2018-2023)
  • Table 94. Africa Active Pharmaceutical Ingredients, by Type USD Million (2018-2023)
  • Table 95. Africa Active Pharmaceutical Ingredients, by Synthesis USD Million (2018-2023)
  • Table 96. Africa Active Pharmaceutical Ingredients, by Manufacturer USD Million (2018-2023)
  • Table 97. Africa Active Pharmaceutical Ingredients, by Therapy Area USD Million (2018-2023)
  • Table 98. North America Active Pharmaceutical Ingredients, by Country USD Million (2018-2023)
  • Table 99. North America Active Pharmaceutical Ingredients, by Type USD Million (2018-2023)
  • Table 100. North America Active Pharmaceutical Ingredients, by Synthesis USD Million (2018-2023)
  • Table 101. North America Active Pharmaceutical Ingredients, by Manufacturer USD Million (2018-2023)
  • Table 102. North America Active Pharmaceutical Ingredients, by Therapy Area USD Million (2018-2023)
  • Table 103. United States Active Pharmaceutical Ingredients, by Type USD Million (2018-2023)
  • Table 104. United States Active Pharmaceutical Ingredients, by Synthesis USD Million (2018-2023)
  • Table 105. United States Active Pharmaceutical Ingredients, by Manufacturer USD Million (2018-2023)
  • Table 106. United States Active Pharmaceutical Ingredients, by Therapy Area USD Million (2018-2023)
  • Table 107. Canada Active Pharmaceutical Ingredients, by Type USD Million (2018-2023)
  • Table 108. Canada Active Pharmaceutical Ingredients, by Synthesis USD Million (2018-2023)
  • Table 109. Canada Active Pharmaceutical Ingredients, by Manufacturer USD Million (2018-2023)
  • Table 110. Canada Active Pharmaceutical Ingredients, by Therapy Area USD Million (2018-2023)
  • Table 111. Mexico Active Pharmaceutical Ingredients, by Type USD Million (2018-2023)
  • Table 112. Mexico Active Pharmaceutical Ingredients, by Synthesis USD Million (2018-2023)
  • Table 113. Mexico Active Pharmaceutical Ingredients, by Manufacturer USD Million (2018-2023)
  • Table 114. Mexico Active Pharmaceutical Ingredients, by Therapy Area USD Million (2018-2023)
  • Table 115. Active Pharmaceutical Ingredients: by Type(USD/Units)
  • Table 116. Company Basic Information, Sales Area and Its Competitors
  • Table 117. Company Basic Information, Sales Area and Its Competitors
  • Table 118. Company Basic Information, Sales Area and Its Competitors
  • Table 119. Company Basic Information, Sales Area and Its Competitors
  • Table 120. Company Basic Information, Sales Area and Its Competitors
  • Table 121. Company Basic Information, Sales Area and Its Competitors
  • Table 122. Company Basic Information, Sales Area and Its Competitors
  • Table 123. Company Basic Information, Sales Area and Its Competitors
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Active Pharmaceutical Ingredients: by Type(USD Million)
  • Table 129. Active Pharmaceutical Ingredients Innovative Active Pharmaceutical Ingredients , by Region USD Million (2025-2030)
  • Table 130. Active Pharmaceutical Ingredients Generic Active Pharmaceutical Ingredients , by Region USD Million (2025-2030)
  • Table 131. Active Pharmaceutical Ingredients: by Synthesis(USD Million)
  • Table 132. Active Pharmaceutical Ingredients Biotech , by Region USD Million (2025-2030)
  • Table 133. Active Pharmaceutical Ingredients Synthetic , by Region USD Million (2025-2030)
  • Table 134. Active Pharmaceutical Ingredients: by Manufacturer(USD Million)
  • Table 135. Active Pharmaceutical Ingredients Captive API Manufacturers , by Region USD Million (2025-2030)
  • Table 136. Active Pharmaceutical Ingredients Merchant API Manufacturers , by Region USD Million (2025-2030)
  • Table 137. Active Pharmaceutical Ingredients: by Therapy Area(USD Million)
  • Table 138. Active Pharmaceutical Ingredients Oncology , by Region USD Million (2025-2030)
  • Table 139. Active Pharmaceutical Ingredients Non-Steroidal Anti-Inflammatory , by Region USD Million (2025-2030)
  • Table 140. Active Pharmaceutical Ingredients Cardiovascular , by Region USD Million (2025-2030)
  • Table 141. Active Pharmaceutical Ingredients Anti-Diabetic , by Region USD Million (2025-2030)
  • Table 142. Active Pharmaceutical Ingredients Neurology [Biperiden HCL, Other Neurology API] , by Region USD Million (2025-2030)
  • Table 143. Active Pharmaceutical Ingredients Musculoskeletal , by Region USD Million (2025-2030)
  • Table 144. Active Pharmaceutical Ingredients Others , by Region USD Million (2025-2030)
  • Table 145. South America Active Pharmaceutical Ingredients, by Country USD Million (2025-2030)
  • Table 146. South America Active Pharmaceutical Ingredients, by Type USD Million (2025-2030)
  • Table 147. South America Active Pharmaceutical Ingredients, by Synthesis USD Million (2025-2030)
  • Table 148. South America Active Pharmaceutical Ingredients, by Manufacturer USD Million (2025-2030)
  • Table 149. South America Active Pharmaceutical Ingredients, by Therapy Area USD Million (2025-2030)
  • Table 150. Brazil Active Pharmaceutical Ingredients, by Type USD Million (2025-2030)
  • Table 151. Brazil Active Pharmaceutical Ingredients, by Synthesis USD Million (2025-2030)
  • Table 152. Brazil Active Pharmaceutical Ingredients, by Manufacturer USD Million (2025-2030)
  • Table 153. Brazil Active Pharmaceutical Ingredients, by Therapy Area USD Million (2025-2030)
  • Table 154. Argentina Active Pharmaceutical Ingredients, by Type USD Million (2025-2030)
  • Table 155. Argentina Active Pharmaceutical Ingredients, by Synthesis USD Million (2025-2030)
  • Table 156. Argentina Active Pharmaceutical Ingredients, by Manufacturer USD Million (2025-2030)
  • Table 157. Argentina Active Pharmaceutical Ingredients, by Therapy Area USD Million (2025-2030)
  • Table 158. Rest of South America Active Pharmaceutical Ingredients, by Type USD Million (2025-2030)
  • Table 159. Rest of South America Active Pharmaceutical Ingredients, by Synthesis USD Million (2025-2030)
  • Table 160. Rest of South America Active Pharmaceutical Ingredients, by Manufacturer USD Million (2025-2030)
  • Table 161. Rest of South America Active Pharmaceutical Ingredients, by Therapy Area USD Million (2025-2030)
  • Table 162. Asia Pacific Active Pharmaceutical Ingredients, by Country USD Million (2025-2030)
  • Table 163. Asia Pacific Active Pharmaceutical Ingredients, by Type USD Million (2025-2030)
  • Table 164. Asia Pacific Active Pharmaceutical Ingredients, by Synthesis USD Million (2025-2030)
  • Table 165. Asia Pacific Active Pharmaceutical Ingredients, by Manufacturer USD Million (2025-2030)
  • Table 166. Asia Pacific Active Pharmaceutical Ingredients, by Therapy Area USD Million (2025-2030)
  • Table 167. China Active Pharmaceutical Ingredients, by Type USD Million (2025-2030)
  • Table 168. China Active Pharmaceutical Ingredients, by Synthesis USD Million (2025-2030)
  • Table 169. China Active Pharmaceutical Ingredients, by Manufacturer USD Million (2025-2030)
  • Table 170. China Active Pharmaceutical Ingredients, by Therapy Area USD Million (2025-2030)
  • Table 171. Japan Active Pharmaceutical Ingredients, by Type USD Million (2025-2030)
  • Table 172. Japan Active Pharmaceutical Ingredients, by Synthesis USD Million (2025-2030)
  • Table 173. Japan Active Pharmaceutical Ingredients, by Manufacturer USD Million (2025-2030)
  • Table 174. Japan Active Pharmaceutical Ingredients, by Therapy Area USD Million (2025-2030)
  • Table 175. India Active Pharmaceutical Ingredients, by Type USD Million (2025-2030)
  • Table 176. India Active Pharmaceutical Ingredients, by Synthesis USD Million (2025-2030)
  • Table 177. India Active Pharmaceutical Ingredients, by Manufacturer USD Million (2025-2030)
  • Table 178. India Active Pharmaceutical Ingredients, by Therapy Area USD Million (2025-2030)
  • Table 179. Australia Active Pharmaceutical Ingredients, by Type USD Million (2025-2030)
  • Table 180. Australia Active Pharmaceutical Ingredients, by Synthesis USD Million (2025-2030)
  • Table 181. Australia Active Pharmaceutical Ingredients, by Manufacturer USD Million (2025-2030)
  • Table 182. Australia Active Pharmaceutical Ingredients, by Therapy Area USD Million (2025-2030)
  • Table 183. Rest of Asia-Pacific Active Pharmaceutical Ingredients, by Type USD Million (2025-2030)
  • Table 184. Rest of Asia-Pacific Active Pharmaceutical Ingredients, by Synthesis USD Million (2025-2030)
  • Table 185. Rest of Asia-Pacific Active Pharmaceutical Ingredients, by Manufacturer USD Million (2025-2030)
  • Table 186. Rest of Asia-Pacific Active Pharmaceutical Ingredients, by Therapy Area USD Million (2025-2030)
  • Table 187. Europe Active Pharmaceutical Ingredients, by Country USD Million (2025-2030)
  • Table 188. Europe Active Pharmaceutical Ingredients, by Type USD Million (2025-2030)
  • Table 189. Europe Active Pharmaceutical Ingredients, by Synthesis USD Million (2025-2030)
  • Table 190. Europe Active Pharmaceutical Ingredients, by Manufacturer USD Million (2025-2030)
  • Table 191. Europe Active Pharmaceutical Ingredients, by Therapy Area USD Million (2025-2030)
  • Table 192. Germany Active Pharmaceutical Ingredients, by Type USD Million (2025-2030)
  • Table 193. Germany Active Pharmaceutical Ingredients, by Synthesis USD Million (2025-2030)
  • Table 194. Germany Active Pharmaceutical Ingredients, by Manufacturer USD Million (2025-2030)
  • Table 195. Germany Active Pharmaceutical Ingredients, by Therapy Area USD Million (2025-2030)
  • Table 196. France Active Pharmaceutical Ingredients, by Type USD Million (2025-2030)
  • Table 197. France Active Pharmaceutical Ingredients, by Synthesis USD Million (2025-2030)
  • Table 198. France Active Pharmaceutical Ingredients, by Manufacturer USD Million (2025-2030)
  • Table 199. France Active Pharmaceutical Ingredients, by Therapy Area USD Million (2025-2030)
  • Table 200. Italy Active Pharmaceutical Ingredients, by Type USD Million (2025-2030)
  • Table 201. Italy Active Pharmaceutical Ingredients, by Synthesis USD Million (2025-2030)
  • Table 202. Italy Active Pharmaceutical Ingredients, by Manufacturer USD Million (2025-2030)
  • Table 203. Italy Active Pharmaceutical Ingredients, by Therapy Area USD Million (2025-2030)
  • Table 204. United Kingdom Active Pharmaceutical Ingredients, by Type USD Million (2025-2030)
  • Table 205. United Kingdom Active Pharmaceutical Ingredients, by Synthesis USD Million (2025-2030)
  • Table 206. United Kingdom Active Pharmaceutical Ingredients, by Manufacturer USD Million (2025-2030)
  • Table 207. United Kingdom Active Pharmaceutical Ingredients, by Therapy Area USD Million (2025-2030)
  • Table 208. Rest of Europe Active Pharmaceutical Ingredients, by Type USD Million (2025-2030)
  • Table 209. Rest of Europe Active Pharmaceutical Ingredients, by Synthesis USD Million (2025-2030)
  • Table 210. Rest of Europe Active Pharmaceutical Ingredients, by Manufacturer USD Million (2025-2030)
  • Table 211. Rest of Europe Active Pharmaceutical Ingredients, by Therapy Area USD Million (2025-2030)
  • Table 212. MEA Active Pharmaceutical Ingredients, by Country USD Million (2025-2030)
  • Table 213. MEA Active Pharmaceutical Ingredients, by Type USD Million (2025-2030)
  • Table 214. MEA Active Pharmaceutical Ingredients, by Synthesis USD Million (2025-2030)
  • Table 215. MEA Active Pharmaceutical Ingredients, by Manufacturer USD Million (2025-2030)
  • Table 216. MEA Active Pharmaceutical Ingredients, by Therapy Area USD Million (2025-2030)
  • Table 217. Middle East Active Pharmaceutical Ingredients, by Type USD Million (2025-2030)
  • Table 218. Middle East Active Pharmaceutical Ingredients, by Synthesis USD Million (2025-2030)
  • Table 219. Middle East Active Pharmaceutical Ingredients, by Manufacturer USD Million (2025-2030)
  • Table 220. Middle East Active Pharmaceutical Ingredients, by Therapy Area USD Million (2025-2030)
  • Table 221. Africa Active Pharmaceutical Ingredients, by Type USD Million (2025-2030)
  • Table 222. Africa Active Pharmaceutical Ingredients, by Synthesis USD Million (2025-2030)
  • Table 223. Africa Active Pharmaceutical Ingredients, by Manufacturer USD Million (2025-2030)
  • Table 224. Africa Active Pharmaceutical Ingredients, by Therapy Area USD Million (2025-2030)
  • Table 225. North America Active Pharmaceutical Ingredients, by Country USD Million (2025-2030)
  • Table 226. North America Active Pharmaceutical Ingredients, by Type USD Million (2025-2030)
  • Table 227. North America Active Pharmaceutical Ingredients, by Synthesis USD Million (2025-2030)
  • Table 228. North America Active Pharmaceutical Ingredients, by Manufacturer USD Million (2025-2030)
  • Table 229. North America Active Pharmaceutical Ingredients, by Therapy Area USD Million (2025-2030)
  • Table 230. United States Active Pharmaceutical Ingredients, by Type USD Million (2025-2030)
  • Table 231. United States Active Pharmaceutical Ingredients, by Synthesis USD Million (2025-2030)
  • Table 232. United States Active Pharmaceutical Ingredients, by Manufacturer USD Million (2025-2030)
  • Table 233. United States Active Pharmaceutical Ingredients, by Therapy Area USD Million (2025-2030)
  • Table 234. Canada Active Pharmaceutical Ingredients, by Type USD Million (2025-2030)
  • Table 235. Canada Active Pharmaceutical Ingredients, by Synthesis USD Million (2025-2030)
  • Table 236. Canada Active Pharmaceutical Ingredients, by Manufacturer USD Million (2025-2030)
  • Table 237. Canada Active Pharmaceutical Ingredients, by Therapy Area USD Million (2025-2030)
  • Table 238. Mexico Active Pharmaceutical Ingredients, by Type USD Million (2025-2030)
  • Table 239. Mexico Active Pharmaceutical Ingredients, by Synthesis USD Million (2025-2030)
  • Table 240. Mexico Active Pharmaceutical Ingredients, by Manufacturer USD Million (2025-2030)
  • Table 241. Mexico Active Pharmaceutical Ingredients, by Therapy Area USD Million (2025-2030)
  • Table 242. Active Pharmaceutical Ingredients: by Type(USD/Units)
  • Table 243. Research Programs/Design for This Report
  • Table 244. Key Data Information from Secondary Sources
  • Table 245. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Active Pharmaceutical Ingredients: by Type USD Million (2018-2023)
  • Figure 5. Global Active Pharmaceutical Ingredients: by Synthesis USD Million (2018-2023)
  • Figure 6. Global Active Pharmaceutical Ingredients: by Manufacturer USD Million (2018-2023)
  • Figure 7. Global Active Pharmaceutical Ingredients: by Therapy Area USD Million (2018-2023)
  • Figure 8. South America Active Pharmaceutical Ingredients Share (%), by Country
  • Figure 9. Asia Pacific Active Pharmaceutical Ingredients Share (%), by Country
  • Figure 10. Europe Active Pharmaceutical Ingredients Share (%), by Country
  • Figure 11. MEA Active Pharmaceutical Ingredients Share (%), by Country
  • Figure 12. North America Active Pharmaceutical Ingredients Share (%), by Country
  • Figure 13. Global Active Pharmaceutical Ingredients: by Type USD/Units (2018-2023)
  • Figure 14. Global Active Pharmaceutical Ingredients share by Players 2023 (%)
  • Figure 15. Global Active Pharmaceutical Ingredients share by Players (Top 3) 2023(%)
  • Figure 16. Global Active Pharmaceutical Ingredients share by Players (Top 5) 2023(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Pfizer, Inc. (United States) Revenue: by Geography 2023
  • Figure 20. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 21. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 22. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 23. Sanofi (France) Revenue: by Geography 2023
  • Figure 24. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 25. Boehringer Ingelheim (Germany) Revenue: by Geography 2023
  • Figure 26. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 27. Bristol-Myers Squibb (United States) Revenue: by Geography 2023
  • Figure 28. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 29. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2023
  • Figure 30. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 31. Eli Lilly and Company (United States) Revenue: by Geography 2023
  • Figure 32. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 33. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2023
  • Figure 34. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Merck & Co., Inc. (United States) Revenue: by Geography 2023
  • Figure 36. Sun Pharmaceutical Industries Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 37. Sun Pharmaceutical Industries Ltd. (India) Revenue: by Geography 2023
  • Figure 38. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 39. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2023
  • Figure 40. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 41. AstraZeneca plc (United Kingdom) Revenue: by Geography 2023
  • Figure 42. Global Active Pharmaceutical Ingredients: by Type USD Million (2025-2030)
  • Figure 43. Global Active Pharmaceutical Ingredients: by Synthesis USD Million (2025-2030)
  • Figure 44. Global Active Pharmaceutical Ingredients: by Manufacturer USD Million (2025-2030)
  • Figure 45. Global Active Pharmaceutical Ingredients: by Therapy Area USD Million (2025-2030)
  • Figure 46. South America Active Pharmaceutical Ingredients Share (%), by Country
  • Figure 47. Asia Pacific Active Pharmaceutical Ingredients Share (%), by Country
  • Figure 48. Europe Active Pharmaceutical Ingredients Share (%), by Country
  • Figure 49. MEA Active Pharmaceutical Ingredients Share (%), by Country
  • Figure 50. North America Active Pharmaceutical Ingredients Share (%), by Country
  • Figure 51. Global Active Pharmaceutical Ingredients: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Pfizer, Inc. (United States)
  • Novartis AG (Switzerland)
  • Sanofi (France)
  • Boehringer Ingelheim (Germany)
  • Bristol-Myers Squibb (United States)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Eli Lilly and Company (United States)
  • GlaxoSmithKline plc (United Kingdom)
  • Merck & Co., Inc. (United States)
  • Sun Pharmaceutical Industries Ltd. (India)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • AstraZeneca plc (United Kingdom)
Additional players considered in the study are as follows:
Olon S.p.A. (Italy) , ZETA (Austria) , AbbVie Inc. (United States) , Corden Pharma (Germany) , Inalco Pharma (United States)
Select User Access Type

Key Highlights of Report


Apr 2024 212 Pages 83 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Active Pharmaceutical Ingredients research Quantitative research analysis
Global Active Pharmaceutical Ingredients research Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Pfizer, Inc. (United States), Novartis AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (United States), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company (United States), GlaxoSmithKline plc (United Kingdom), Merck & Co., Inc. (United States), Sun Pharmaceutical Industries Ltd. (India), F. Hoffmann-La Roche Ltd. (Switzerland) and AstraZeneca plc (United Kingdom) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Growing Focus of Biopharmaceutical Industry on Gene Editing Technology " is seen as one of major influencing trends for Active Pharmaceutical Ingredients Market during projected period 2023-2030.
The Active Pharmaceutical Ingredients market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Active Pharmaceutical Ingredients research Report?

Have a Query? Click Here

Other Related Reports

Nootropics Comprehensive Study by Application (ADHD, Alzheimer, Narcolepsy, Memory Enhancement, Mood and Depression, Anxiety, Others), Drug (Prescription (Modafinil, Adderall, Methylphenidate, Memant...
$ 3750
Inositol Comprehensive Study by Type (Myo-inositol, D-chiro-inositol), Nature (Organic, Conventional), Industry Verticals (Pharmaceuticals, Food & Beverages, Cosmetic, Feed Additive), Distribution Ch...
$ 3650
Fertility Drugs Comprehensive Study by Type (Prescription Fertility Drugs, Over-The-Counter Fertility drugs), Application (Fertility Centers, Hospitals & Surgical Clinics, Cryobanks, Research Institu...
$ 3750
Oral Contraceptive Drugs Comprehensive Study by Type (Long-acting Contraceptives, Short-acting Contraceptives, Emergency Contraceptives), Application (Hospital, Pharmacy, Other), Distribution Channel...
$ 3500
Custom Antibody Comprehensive Study by Type (Monoclonal, Polyclonal, Recombinant), End-Users (Hospitals and Clinics, Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Contract...
$ 3650
Pemetrexed Drug Comprehensive Study by Application (Pleural mesothelioma, Lung Cancer, Colorectal Cancer, Stomach Cancer, Breast Cancer), Distribution Channel (Online, Offline), Strength (100 mg lyop...
$ 3450